Theratechnologies Competitors

Theratechnologies (NASDAQ:THTX) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Zymeworks, as provided by MarketBeat.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Zymeworks has a consensus price target of $51.50, indicating a potential upside of 66.13%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Zymeworks.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 75.1% of Zymeworks shares are owned by institutional investors. 4.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Zymeworks' revenue, earnings per share (EPS) and valuation.

Theratechnologies has higher revenue and earnings than Zymeworks. Theratechnologies is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Zymeworks' net margins, return on equity and return on assets.

Summary

Zymeworks beats Theratechnologies on 8 of the 15 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Endo International (NASDAQ:ENDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Endo International, as provided by MarketBeat.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Endo International has a consensus price target of $7.6667, indicating a potential upside of 23.66%. Given Theratechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Theratechnologies is more favorable than Endo International.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 80.0% of Endo International shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Endo International has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Endo International's revenue, earnings per share (EPS) and valuation.

Theratechnologies has higher earnings, but lower revenue than Endo International. Theratechnologies is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Endo International's net margins, return on equity and return on assets.

Summary

Endo International beats Theratechnologies on 8 of the 13 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Zealand Pharma A/S (NASDAQ:ZEAL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Zealand Pharma A/S, as provided by MarketBeat.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Zealand Pharma A/S has a consensus price target of $43.00, indicating a potential upside of 31.10%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Zealand Pharma A/S.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Theratechnologies and Zealand Pharma A/S's revenue, earnings per share (EPS) and valuation.

Theratechnologies has higher revenue and earnings than Zealand Pharma A/S. Theratechnologies is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Zealand Pharma A/S's net margins, return on equity and return on assets.

Summary

Theratechnologies beats Zealand Pharma A/S on 10 of the 13 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Theratechnologies and Keros Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Theratechnologies and Keros Therapeutics, as provided by MarketBeat.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Keros Therapeutics has a consensus price target of $78.00, indicating a potential upside of 29.65%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Keros Therapeutics.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 58.4% of Keros Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Theratechnologies and Keros Therapeutics' revenue, earnings per share (EPS) and valuation.

Keros Therapeutics has lower revenue, but higher earnings than Theratechnologies.

Summary

Keros Therapeutics beats Theratechnologies on 6 of the 8 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Theratechnologies and Theravance Biopharma's net margins, return on equity and return on assets.

Volatility & Risk

Theratechnologies has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Theravance Biopharma, as provided by MarketBeat.com.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Theravance Biopharma has a consensus price target of $33.2857, indicating a potential upside of 58.88%. Given Theratechnologies' higher possible upside, equities analysts plainly believe Theratechnologies is more favorable than Theravance Biopharma.

Institutional & Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are owned by institutional investors. 5.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Theratechnologies and Theravance Biopharma's revenue, earnings per share and valuation.

Theratechnologies has higher earnings, but lower revenue than Theravance Biopharma. Theratechnologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Theravance Biopharma beats Theratechnologies on 8 of the 14 factors compared between the two stocks.

Theratechnologies (NASDAQ:THTX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares Theratechnologies and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Theratechnologies currently has a consensus price target of $7.1250, indicating a potential upside of 86.52%. Arcutis Biotherapeutics has a consensus price target of $54.6667, indicating a potential upside of 105.36%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Theratechnologies.

Institutional & Insider Ownership

6.3% of Theratechnologies shares are owned by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Theratechnologies and Arcutis Biotherapeutics' revenue, earnings per share and valuation.

Theratechnologies has higher revenue and earnings than Arcutis Biotherapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arcutis Biotherapeutics beats Theratechnologies on 7 of the 11 factors compared between the two stocks.